Cirio advises Abliva on its SEK 200 million financing to fund phase 2/3 study

Cirio acted as legal adviser to Abliva AB (publ) in connection with its directed issue of approximately SEK 150 million to life science specialist and institutional investors, and the fully underwritten rights issue of approximately SEK 50 million. The issues were conducted to fund the phase 2/3 study of KL1333, a potent modulator of the NAD+/NADH coenzymes involved in cell’s energy metabolism for the treatment of primary mitochondrial disease.

Cirio’s team is headed by Annika Andersson, with the assistance of Sebastian Iso-Kamula, Rebecka Tallberg, Julia Alander (Capital Markets and Public M&A), Anders Burén, Hanna Tilus, Säde Kanervisto (Life Sciences) and Dennis Luttropp Hansson (Banking & Finance).

For more information, please contact: